Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F22%3AN0000014" target="_blank" >RIV/00023728:_____/22:N0000014 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/22:10442308 RIV/00216208:11110/22:10442308 RIV/00216208:11130/22:10442308

Výsledek na webu

<a href="https://doi.org/10.1177/1759720X221081649" target="_blank" >https://doi.org/10.1177/1759720X221081649</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1759720X221081649" target="_blank" >10.1177/1759720X221081649</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Popis výsledku v původním jazyce

The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-alpha inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA), a TNF-alpha blocker, in patients with axial spondyloarthritis (AxSpA). This study was a historical prospective, registry-based observational study on patients with AxSpA treated with first-line ADA after conventional drug failure. For evaluation and comparison, patients were divided into three groups according to the number of years from AxSpA diagnosis to initiation of ADA treatment: (A) <5years, (B) 5-10years, and (C) >10years. The assessment instruments ankylosing spondylitis disease activity score (ASDAS), Bath ankylosing spondylitis activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), health assessment questionnaire (HAQ), Short Form 36 questionnaire (SF-36), and EuroQoL 5 dimension questionnaire (EQ-5D] were regularly administered for up to 24 months of follow-up. This study included 1043 patients with AxSpA (9.2% with non-radiographic AxSpA, 68.9% men). By month 6, a significantly higher proportion of patients with ASDAS remission (<1.3) was achieved upon earlier intervention in group A (30.1%) and B (32.9%) than in the late intervention group C (22.6%) (p <= 0.05). At month 6, lower age and better BASFI at treatment initiation were identified as the strongest predictors of ASDAS remission in both univariable [odds ratio (OR): 0.956, p <= 0.001; OR: 0.834, p <= 0.001, respectively] and multivariable analyses (OR: 0.963, p <= 0.001; OR: 0.859, p <= 0.001, respectively). Earlier intervention also led to improvement in most patient-reported outcomes (PROs) based on HAQ, SF-36, and EQ-5D. Results from the ATTRA registry concur with previous clinical trials that supported efficacy of TNF-alpha blockers and showed better treatment outcomes with early interventions, including reduction of disease activity and improvement in PROs. We identified age and BASFI as the main factors influencing treatment effectiveness

Název v anglickém jazyce

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

Popis výsledku anglicky

The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-alpha inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA), a TNF-alpha blocker, in patients with axial spondyloarthritis (AxSpA). This study was a historical prospective, registry-based observational study on patients with AxSpA treated with first-line ADA after conventional drug failure. For evaluation and comparison, patients were divided into three groups according to the number of years from AxSpA diagnosis to initiation of ADA treatment: (A) <5years, (B) 5-10years, and (C) >10years. The assessment instruments ankylosing spondylitis disease activity score (ASDAS), Bath ankylosing spondylitis activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), health assessment questionnaire (HAQ), Short Form 36 questionnaire (SF-36), and EuroQoL 5 dimension questionnaire (EQ-5D] were regularly administered for up to 24 months of follow-up. This study included 1043 patients with AxSpA (9.2% with non-radiographic AxSpA, 68.9% men). By month 6, a significantly higher proportion of patients with ASDAS remission (<1.3) was achieved upon earlier intervention in group A (30.1%) and B (32.9%) than in the late intervention group C (22.6%) (p <= 0.05). At month 6, lower age and better BASFI at treatment initiation were identified as the strongest predictors of ASDAS remission in both univariable [odds ratio (OR): 0.956, p <= 0.001; OR: 0.834, p <= 0.001, respectively] and multivariable analyses (OR: 0.963, p <= 0.001; OR: 0.859, p <= 0.001, respectively). Earlier intervention also led to improvement in most patient-reported outcomes (PROs) based on HAQ, SF-36, and EQ-5D. Results from the ATTRA registry concur with previous clinical trials that supported efficacy of TNF-alpha blockers and showed better treatment outcomes with early interventions, including reduction of disease activity and improvement in PROs. We identified age and BASFI as the main factors influencing treatment effectiveness

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

<a href="/cs/project/NU20-05-00320" target="_blank" >NU20-05-00320: Role neutrofilů u juvenilní idiopatické artritidy jako potenciálních biomarkerů předurčujících odpovídavost na biologickou léčbu</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Therapeutic Advances Musculoskeletal Disease

ISSN

1759-720X

e-ISSN

1759-7218

Svazek periodika

14

Číslo periodika v rámci svazku

Art. Nr. 1759720X221081649.

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

13

Strana od-do

1-13

Kód UT WoS článku

000772688100001

EID výsledku v databázi Scopus

2-s2.0-85126758508